Close

Mylan Pharmaceuticals launches Fenofibrate Capsules

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

Navigating Pharma Market Growth: CDMO Strategies For 2025

By the year 2025, it is projected that the...

Revolutionary Drug Delivery System With Nanoparticle Tech

When Willus Fisher, a doctorate candidate at the University...

Revolutionizing Biologics : Inhalation And Liquid Delivery

It is noteworthy that the pharmaceutical industry is gradually...

Mylan Pharmaceuticals, a subsidiary of global pharmaceutical company Mylan, has launched Fenofibrate Capsules USP, 43 mg and 130 mg.

Fenofibrate Capsules, which are generic equivalent to Lupin Atlantis Holdings’ Antara Capsules, are indicated as an adjunct to diet to reduce elevated LDL-C, Total-C and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.

In addition, Fenofibrate Capsules reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Fenofibrate has not been shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus, according to Mylan,

According to IMS Health, Mylan currently has 184 ANDAs pending FDA approval representing $80.7bn in annual sales, out of which 36 pending ANDAs are potential first-to-file opportunities, representing $21.1bn in annual brand sales, for the 12 months ending 30 June 2012.

 

Latest stories